title: Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States.
authors.affiliation: Analysis Group, Inc., Boston, Massachusetts, USA.
authors.forename: Noam Y
authors.initials: NY
authors.lastname: Kirson
authors.forename: Amie
authors.initials: A
authors.lastname: Shei
authors.forename: Alan G
authors.initials: AG
authors.lastname: White
authors.forename: Howard G
authors.initials: HG
authors.lastname: Birnbaum
authors.forename: Rami
authors.initials: R
authors.lastname: Ben-Joseph
authors.forename: Louis F
authors.initials: LF
authors.lastname: Rossiter
authors.forename: Edward
authors.initials: E
authors.lastname: Michna
mesh_terms: D000041:Absenteeism; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics*; D002626:Chemistry, Pharmaceutical / Q000191:economics; D017046:Cost Savings; D017281:Cost of Illness; D003416:Criminal Law / Q000191:economics; D003692:Delayed-Action Preparations; D016527:Drug Costs; D004348:Drug Labeling; D017048:Health Care Costs; D005102:Health Expenditures; D006801:Humans; D009293:Opioid-Related Disorders / Q000453:epidemiology / Q000517:prevention & control*; D010098:Oxycodone / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics*; D012106:Research / Q000191:economics; D013678:Technology, Pharmaceutical / Q000191:economics; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration
chemical_list: D000701:Analgesics, Opioid; D003692:Delayed-Action Preparations; D010098:Oxycodone